GALDERMA GRP AG
197,00€
+5,00 (+2,60%)
29.06.2026, 14:32:24 Uhr
WKN: A407X6 ISIN: CH1335392721 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Weltmärkte
- DAX ® +7,62 +0,03% 24.678,84
- MDAX ® -383,99 -1,20% 31.588,65
- TecDAX ® -32,56 -0,84% 3.860,16
- E-STOXX 50 ® -45,98 -0,73% 6.221,55
- NASDAQ 100 -322,08 -1,09% 29.118,24
- HANG SENG +336,33 +1,48% 23.026,68
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | 192,00€ | +2,60% |
| 1 Woche | 185,00€ | +3,78% |
| 1 Monat | 173,00€ | +10,98% |
| 6 Monate | -- | -- |
| Lfd. Jahr (YTD) | -- | -- |
| 1 Jahr | -- | -- |
| 3 Jahre | -- | -- |
| 5 Jahre | -- | -- |
Kursdaten
| Kurs | 197,00€ |
| Schluss Vortag | 192,00€ |
| Eröffnung | 193,00€ |
| Geld | 197,00€ |
| Brief | 197,00€ |
| Tages-Hoch | 197,00€ |
| Tages-Tief | 193,00€ |
| 52 Wochen-Hoch | 200,00€ |
| 52 Wochen-Tief | 149,00€ |
| Allzeit-Hoch | 200,00€ |
| Allzeit-Tief | 149,00€ |
Nachrichten
- BUSINESS WIRE: Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments - 11.06.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch - 22.05.2026, 18:25:04 Uhr
- BUSINESS WIRE: Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency - 23.04.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Shareholders Approve All Annual General Meeting Proposals - 22.04.2026, 17:45:02 Uhr
- BUSINESS WIRE: Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform - 16.04.2026, 07:00:02 Uhr
- BUSINESS WIRE: Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause - 09.04.2026, 07:00:05 Uhr
- BUSINESS WIRE: AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis - 28.03.2026, 16:00:03 Uhr
- BUSINESS WIRE: AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs - 24.03.2026, 07:00:05 Uhr
- BUSINESS WIRE: Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing - 23.03.2026, 07:00:05 Uhr
- BUSINESS WIRE: Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting - 20.03.2026, 06:55:01 Uhr
